目的:探讨舒尼替尼相关性甲状腺功能减退与晚期肾细胞癌的预后关系。方法:选取2009-04-30-2012-11-30中国医学科学院肿瘤医院晚期肾细胞癌患者38例,均行原发肾脏病灶手术切除,病理确诊为肾透明细胞癌。治疗方案:舒尼替尼50mg,1次/d,治疗4周停2周为1个周期;至少每2个周期行影像学检查确定疗效。每2~4周随诊甲状腺功能。结果:随访时间2~44个月,14例随访过程中出现甲状腺功能减退,24例未出现甲状腺功能减退。甲状腺功能减退组,完全缓解(CR)1例(7.14%),部分缓解(PR)5例(35.72%),疾病稳定(SD)8例(57.14%)。甲状腺功能正常组,CR 1例(4.17%),PR 2例(8.33%),SD 18例(75.00%),疾病进展(PD)3例(12.50%)。甲状腺功能正常组中位疾病无进展时间9个月(95%CI:4.6~13.4),中位生存时间20个月(95%CI:4.9~35.1)。甲状腺功能减退组患者未达到中位疾病无进展时间和中位生存时间。常见的药物不良反应包括手足综合征、乏力、白细胞减少、血小板减少、口腔黏膜炎和高血压等,两组差异无统计学意义。结论:在舒尼替尼治疗中出现甲状腺功能减退的晚期肾细胞癌患者的中位无疾病进展时间较长,可能获得更长的中位生存时间。 Objective: To investigate the relationship between sunitinib-associated hypothyroidism and the prognosis of advanced renal cell carcinoma. Methods: Thirty-eight patients with advanced renal cell carcinoma of Cancer Hospital of Chinese Academy of Medical Sciences were selected for 2009-04-30-2012-11-30. All patients underwent primary renal neoplasm resection. The pathological diagnosis was renal clear cell carcinoma. Treatment options: Sunitinib 50mg, 1 / d, treatment for 4 weeks to stop for 2 weeks for a cycle; at least every 2 cycles to determine the efficacy of imaging. Every 2 to 4 weeks follow-up thyroid function. Results: The follow-up time ranged from 2 to 44 months. Hypothyroidism occurred in 14 cases during follow-up and no hypothyroidism occurred in 24 cases. In the hypothyroidism group, one patient (7.14%) had complete remission (CR), five patients (35.72%) had partial remission (PR) and eight patients (57.14%) had stable disease (SD). In the group of normal thyroid function, CR was 1 case (4.17%), PR 2 cases (8.33%), SD 18 cases (75.00%) and disease progression (PD) 3 cases (12.50%). Patients with normal thyroid function had a median progression of 9 months (95% CI: 4.6 to 13.4) and a median survival time of 20 months (95% CI: 4.9 to 35.1). Patients with hypothyroidism did not achieve median progression-free time and median survival. Common adverse drug reactions include hand-foot syndrome, fatigue, leukopenia, thrombocytopenia, oral mucositis and hypertension, no significant difference between the two groups. Conclusion: Patients with advanced renal cell carcinoma who have hypothyroidism during sunitinib therapy have a longer median progression-free age and may achieve longer median survival.